| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $91,250 | 12 | 100 |
Sells | $0 | 0 | 0 |
| Bitterman Robert J | Chairman, Pres. & CEO | 7 | $44,858 | 0 | $0 | $44,858 |
| Plott Ronald Todd | director | 3 | $27,450 | 0 | $0 | $27,450 |
| BRADFORD PATRICIA A | director | 2 | $18,943 | 0 | $0 | $18,943 |
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name …
Over the last 12 months, insiders at Phio Pharmaceuticals Corp. have bought $91,250 and sold $0 worth of Phio Pharmaceuticals Corp. stock.
On average, over the past 5 years, insiders at Phio Pharmaceuticals Corp. have bought $35,528 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bitterman Robert J (Chairman, Pres. & CEO) — $44,858. Plott Ronald Todd (director) — $27,450. BRADFORD PATRICIA A (director) — $18,943.
The last purchase of 5,000 shares for transaction amount of $5,200 was made by Plott Ronald Todd (director) on 2026‑09‑29.
| 2026-09-29 | Plott Ronald Todd | director | 5,000 0.0435% | $1.04 | $5,200 | -10.99% | ||
| 2026-09-28 | Plott Ronald Todd | director | 5,000 0.0439% | $1.03 | $5,150 | -8.97% | ||
| 2026-09-24 | BRADFORD PATRICIA A | director | 6,500 0.0556% | $1.01 | $6,583 | -9.42% | ||
| 2026-09-22 | Bitterman Robert J | Chairman, Pres. & CEO | 2,000 0.0172% | $1.03 | $2,058 | -6.99% | ||
| 2026-09-15 | BRADFORD PATRICIA A | director | 12,000 0.1043% | $1.03 | $12,360 | -4.60% | ||
| 2026-08-19 | Plott Ronald Todd | director | 15,000 0.128% | $1.14 | $17,100 | -12.17% | ||
| 2026-08-18 | Bitterman Robert J | Chairman, Pres. & CEO | 10,000 0.0869% | $1.06 | $10,600 | -3.81% | ||
| 2026-06-26 | Bitterman Robert J | Chairman, Pres. & CEO | 10,000 0.0879% | $0.99 | $9,900 | +5.15% | ||
| 2025-12-31 | Bitterman Robert J | Chairman, Pres. & CEO | 5,000 0.0469% | $1.03 | $5,150 | +2.86% | ||
| 2025-12-23 | Bitterman Robert J | Chairman, Pres. & CEO | 5,000 0.0431% | $1.02 | $5,100 | +4.85% | ||
| 2025-11-21 | Bitterman Robert J | Chairman, Pres. & CEO | 5,000 0.1061% | $1.14 | $5,700 | -3.57% | ||
| 2025-11-18 | Bitterman Robert J | Chairman, Pres. & CEO | 5,000 0.1042% | $1.27 | $6,350 | -14.96% | ||
| 2025-06-10 | Bitterman Robert J | Chairman, Pres & CEO | 2,000 0.0408% | $2.42 | $4,840 | -48.58% | ||
| 2025-06-10 | Ferrara Robert L | director | 2,500 0.051% | $2.42 | $6,050 | -48.58% | ||
| 2025-06-09 | Bitterman Robert J | Chairman, Pres & CEO | 1,500 0.0308% | $2.75 | $4,125 | -54.48% | ||
| 2025-05-22 | Bitterman Robert J | Chairman, Pres & CEO | 1,200 0.0242% | $1.78 | $2,136 | -28.26% | ||
| 2025-05-21 | Bitterman Robert J | Chairman, Pres & CEO | 3,000 0.0618% | $1.77 | $5,310 | -26.26% | ||
| 2025-05-20 | Ferrara Robert L | director | 2,500 0.0518% | $1.82 | $4,550 | -26.23% | ||
| 2024-06-07 | Bitterman Robert J | President & CEO | 1,000 0.0216% | $0.74 | $740 | -60.95% | ||
| 2024-06-06 | Bitterman Robert J | President & CEO | 1,000 0.0218% | $0.75 | $750 | -61.19% |
| Bitterman Robert J | Chairman, Pres. & CEO | 364871 3.1408% | $329,478.51 | 25 | 0 | <0.0001% |
| BRADFORD PATRICIA A | director | 64151 0.5522% | $57,928.35 | 2 | 0 | |
| Plott Ronald Todd | director | 42000 0.3615% | $37,926.00 | 3 | 0 | |
| Advanced RNA Technologies, LLC | 1221723 10.5165% | $1.1M | 1 | 0 | ||
| CAUWENBERGH GEERT | President & CEO | 142583 1.2273% | $128,752.45 | 60 | 0 | |
| Dispersyn Gerrit | President & CEO | 95281 0.8202% | $86,038.74 | 5 | 0 | <0.0001% |
| Ferrara Robert L | director | 15666 0.1349% | $14,146.40 | 6 | 0 | <0.0001% |
| Lockshin Curtis | director | 1000 0.0086% | $903.00 | 1 | 0 |
$18,815,063 | 62 | -6.45% | $13.7M | |
$1,993,425 | 46 | -21.91% | $13.95M | |
$95,567,744 | 39 | -17.01% | $10.94M | |
$30,257,839 | 29 | -15.72% | $12M | |
Phio Pharmaceuticals Corp. (PHIO) | $76,600 | 22 | -38.58% | $10.49M |
| Increased Positions | 13 | +162.5% | 176,181 | +93.47% |
| Decreased Positions | 2 | -25% | 819 | -0.43% |
| New Positions | 8 | New | 123,821 | New |
| Sold Out Positions | 2 | Sold Out | 819 | Sold Out |
| Total Postitions | 19 | +137.5% | 363,848 | +93.04% |
| Vanguard Group Inc | $96.00 | 0.8% | 87,628 | +38,963 | +80.06% | 2025-09-30 |
| Geode Capital Management, Llc | $63.00 | 0.53% | 57,906 | +212 | +0.37% | 2025-09-30 |
| Cetera Investment Advisers | $37.00 | 0.31% | 33,500 | +1,000 | +3.08% | 2025-09-30 |
| Morgan Stanley | $7.00 | 0.06% | 6,000 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $2.00 | 0.01% | 1,400 | +1,354 | +2,943.48% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $1.00 | 0.01% | 1,101 | -808 | -42.33% | 2025-09-30 |
| Bnp Paribas Financial Markets | $0 | <0.01% | 413 | +413 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $0 | <0.01% | 406 | +406 | New | 2025-09-30 |
| Assetmark, Inc | $0 | <0.01% | 110 | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $0 | 0% | 13 | +13 | New | 2025-09-30 |